Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a ...
BioPharma Dive

Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease

The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group ...

Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion

Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in ...
TMCnet

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is ...
Business Insider

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc., a biotechnology company advancing a novel RNA Overwriting platform, today announced the peer-reviewed publication of preclinical ...
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...